756 results on '"Bertolotto, Antonio"'
Search Results
2. The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT)
3. Prevalence of elevated sNFL in a real-world setting: Results on 908 patients with different multiple sclerosis types and treatment conditions
4. Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study
5. Applying multidimensional computerized adaptive testing to the MSQOL-54: a simulation study
6. Tailoring Rituximab According to CD27-Positive B-Cell versus CD19-Positive B-Cell Monitoring in Neuromyelitis Optica Spectrum Disorder and MOG-Associated Disease: Results from a Single-Center Study
7. Cerebrospinal fluid neurofilament light chains predicts early disease-activity in Multiple Sclerosis
8. Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis
9. The impact of pre-freezing storage time and temperature on gene expression of blood collected in EDTA tubes
10. Identifying and predicting amyotrophic lateral sclerosis clinical subgroups: a population-based machine-learning study
11. PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study
12. Analysis of the Gadolinium retention in the Experimental Autoimmune Encephalomyelitis (EAE) murine model of Multiple Sclerosis
13. Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study
14. Assessing measurement invariance of MSQOL-54 across Italian and English versions
15. Fingolimod as first-line treatment in pediatric-onset multiple sclerosis: a case report
16. Coverage of the requirements of first and second level stroke unit in Italy
17. The reliability of objective fatigue measures in Multiple Sclerosis Patients
18. Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Standard of Care for Relapsing–Remitting Multiple Sclerosis Patients
19. Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies
20. Viability of a MSQOL-54 general health-related quality of life score using bifactor model
21. Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset
22. Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study
23. Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis
24. Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis
25. Acknowledgement to Authors, Referees and Readers 2019
26. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting
27. Access to social security benefits among multiple sclerosis patients in Italy: A cross-sectional study.
28. Biological activity of glatiramer acetate on Treg and anti-inflammatory monocytes persists for more than 10 years in responder multiple sclerosis patients
29. Computerized posturography is more sensitive than clinical Romberg Test in detecting postural control impairment in minimally impaired Multiple Sclerosis patients
30. Neurology and Therapy: Looking Back on 2018 and Forward to 2019
31. Authors’ Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl®
32. Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders
33. NURR1 deficiency is associated to ADHD-like phenotypes in mice
34. Anal sphincter dysfunction in multiple sclerosis: an observation manometric study
35. Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach
36. A Comprehensive Review on Copemyl®
37. A20 in Multiple Sclerosis and Parkinson’s Disease: Clue to a Common Dysregulation of Anti-Inflammatory Pathways?
38. High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study
39. Quality of life and patient preferences: identification of subgroups of multiple sclerosis patients
40. Reversible disconnection syndrome in a case of acute tumefactive demyelinating lesion: a PET study
41. CD19 mRNA quantification improves rituximab treatment-to-target approach: A proof of concept study
42. sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients
43. Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis
44. Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective study
45. Prevalence of Posttraumatic Stress Disorder in Patients With Multiple Sclerosis
46. Clinical Aspects of Immunogenicity to Biopharmaceuticals
47. Acknowledgement to Authors, Referees, and Readers
48. Altered NR4A Subfamily Gene Expression Level in Peripheral Blood of Parkinson’s and Alzheimer’s Disease Patients
49. Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers
50. The role of fatigue in the associations between exercise and psychological health in Multiple Sclerosis: Direct and indirect effects
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.